Psychological well‐being (secondary outcome) Not addressed · people within 3 months after stroke
2 findings from 1 review
Satisfaction with intervention (secondary outcome) Not addressed · people within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Marital/relationship/partner satisfaction (secondary outcome) Not addressed · people within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: all adverse events · people within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sexual satisfaction · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Psychological well‐being (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with intervention (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Marital/relationship/partner satisfaction (secondary outcome) · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
1 finding from 1 review
Secondary outcome: all adverse events · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
1 finding from 1 review
Effect on later sexual function · people within 3 months after stroke
1 finding from 1 review
Sexual satisfaction · people within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in any thromboembolic event compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Any bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any bleedingb compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent may leads to higher any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).
1 finding from 1 review